Arch Biopartners Inc. (ACHFF)
USD 1.1
(-7.56%)
USD 1.1
(-7.56%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 5.01 Million CAD | 13.67% |
| 2022 | 4.41 Million CAD | -14.54% |
| 2021 | 5.16 Million CAD | 52.31% |
| 2020 | 3.39 Million CAD | 17.51% |
| 2019 | 2.88 Million CAD | 94.51% |
| 2018 | 1.48 Million CAD | 324.46% |
| 2017 | 349.44 Thousand CAD | 5.82% |
| 2016 | 330.21 Thousand CAD | 0.59% |
| 2015 | 328.27 Thousand CAD | -7.13% |
| 2014 | 353.47 Thousand CAD | -10.77% |
| 2013 | 396.14 Thousand CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| 2010 | - CAD | 0.0% |
| 2009 | - CAD | -100.0% |
| 2008 | 1.64 Million CAD | 21.42% |
| 2007 | 1.35 Million CAD | 43.91% |
| 2006 | 940.38 Thousand CAD | -11.16% |
| 2005 | 1.05 Million CAD | -8.19% |
| 2004 | 1.15 Million CAD | 103.56% |
| 2003 | 566.41 Thousand CAD | -30.35% |
| 2002 | 813.17 Thousand CAD | 586.97% |
| 2001 | 118.37 Thousand CAD | 0.0% |
| 2000 | - CAD | 0.0% |
| 1999 | - CAD | 0.0% |
| 1998 | - CAD | 0.0% |
| 1997 | - CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 4.95 Million CAD | -1.61% |
| 2024 Q3 | 5.32 Million CAD | 7.44% |
| 2024 Q1 | 5.03 Million CAD | 0.41% |
| 2023 FY | 5.01 Million CAD | 13.67% |
| 2023 Q4 | 5.01 Million CAD | 0.76% |
| 2023 Q1 | 4.39 Million CAD | -0.49% |
| 2023 Q3 | 4.97 Million CAD | -15.93% |
| 2023 Q2 | 5.92 Million CAD | 34.85% |
| 2022 Q1 | 4.38 Million CAD | -15.09% |
| 2022 FY | 4.41 Million CAD | -14.54% |
| 2022 Q4 | 4.41 Million CAD | 0.57% |
| 2022 Q2 | 4.36 Million CAD | -0.49% |
| 2022 Q3 | 4.38 Million CAD | 0.57% |
| 2021 Q2 | 3.39 Million CAD | 0.01% |
| 2021 Q3 | 5.64 Million CAD | 66.4% |
| 2021 Q4 | 5.16 Million CAD | -8.49% |
| 2021 FY | 5.16 Million CAD | 52.31% |
| 2021 Q1 | 3.39 Million CAD | 0.01% |
| 2020 Q3 | 3.39 Million CAD | 0.13% |
| 2020 Q4 | 3.39 Million CAD | -0.23% |
| 2020 FY | 3.39 Million CAD | 17.51% |
| 2020 Q2 | 3.39 Million CAD | 17.46% |
| 2020 Q1 | 2.88 Million CAD | 0.15% |
| 2019 Q2 | 1.94 Million CAD | 34.22% |
| 2019 Q1 | 1.44 Million CAD | -2.55% |
| 2019 Q3 | 2.94 Million CAD | 51.81% |
| 2019 Q4 | 2.88 Million CAD | -2.04% |
| 2019 FY | 2.88 Million CAD | 94.51% |
| 2018 Q3 | 1.46 Million CAD | 0.96% |
| 2018 FY | 1.48 Million CAD | 324.46% |
| 2018 Q4 | 1.48 Million CAD | 1.31% |
| 2018 Q2 | 1.45 Million CAD | 70.68% |
| 2018 Q1 | 849.61 Thousand CAD | 143.13% |
| 2017 Q4 | 349.44 Thousand CAD | 9.24% |
| 2017 FY | 349.44 Thousand CAD | 5.82% |
| 2017 Q1 | 334.16 Thousand CAD | 1.19% |
| 2017 Q2 | 334.19 Thousand CAD | 0.01% |
| 2017 Q3 | 319.88 Thousand CAD | -4.28% |
| 2016 FY | 330.21 Thousand CAD | 0.59% |
| 2016 Q4 | 330.21 Thousand CAD | -0.79% |
| 2016 Q2 | 338.2 Thousand CAD | 1.5% |
| 2016 Q1 | 333.2 Thousand CAD | 1.5% |
| 2016 Q3 | 332.83 Thousand CAD | -1.59% |
| 2015 Q2 | 317.39 Thousand CAD | -2.7% |
| 2015 Q1 | 326.2 Thousand CAD | -7.71% |
| 2015 Q4 | 328.27 Thousand CAD | 2.09% |
| 2015 FY | 328.27 Thousand CAD | -7.13% |
| 2015 Q3 | 321.54 Thousand CAD | 1.31% |
| 2014 FY | 353.47 Thousand CAD | -10.77% |
| 2014 Q4 | 353.47 Thousand CAD | -3.98% |
| 2014 Q3 | 368.11 Thousand CAD | -3.85% |
| 2014 Q1 | 25.2 Thousand CAD | -93.64% |
| 2014 Q2 | 382.86 Thousand CAD | 1419.29% |
| 2013 Q3 | 387.83 Thousand CAD | 2.77% |
| 2013 Q4 | 396.14 Thousand CAD | 2.14% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q2 | 377.38 Thousand CAD | 0.0% |
| 2013 FY | 396.14 Thousand CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2010 Q2 | - CAD | 0.0% |
| 2010 FY | - CAD | 0.0% |
| 2010 Q1 | - CAD | 0.0% |
| 2010 Q3 | - CAD | 0.0% |
| 2010 Q4 | - CAD | 0.0% |
| 2009 Q4 | - CAD | 0.0% |
| 2009 FY | - CAD | -100.0% |
| 2009 Q1 | 1.64 Million CAD | -47.87% |
| 2009 Q2 | 1.18 Million CAD | -27.61% |
| 2009 Q3 | - CAD | -100.0% |
| 2008 Q4 | 3.15 Million CAD | 34.58% |
| 2008 Q1 | 1.35 Million CAD | -21.85% |
| 2008 Q2 | 1.98 Million CAD | 46.5% |
| 2008 FY | 1.64 Million CAD | 21.42% |
| 2008 Q3 | 2.34 Million CAD | 18.14% |
| 2007 FY | 1.35 Million CAD | 43.91% |
| 2007 Q4 | 1.73 Million CAD | 72.95% |
| 2007 Q3 | 1 Million CAD | 4.73% |
| 2007 Q2 | 956.05 Thousand CAD | 1.67% |
| 2007 Q1 | 940.38 Thousand CAD | -15.76% |
| 2006 FY | 940.38 Thousand CAD | -11.16% |
| 2006 Q4 | 1.11 Million CAD | 8.46% |
| 2006 Q3 | 1.02 Million CAD | 3.46% |
| 2006 Q2 | 994.81 Thousand CAD | -6.02% |
| 2006 Q1 | 1.05 Million CAD | -2.24% |
| 2005 Q4 | 1.08 Million CAD | 17.16% |
| 2005 Q2 | 1.04 Million CAD | -9.28% |
| 2005 Q1 | 1.15 Million CAD | -0.83% |
| 2005 FY | 1.05 Million CAD | -8.19% |
| 2005 Q3 | 924.18 Thousand CAD | -11.64% |
| 2004 Q2 | 782.35 Thousand CAD | 38.12% |
| 2004 Q1 | 566.41 Thousand CAD | 0.0% |
| 2004 FY | 1.15 Million CAD | 103.56% |
| 2004 Q4 | 1.16 Million CAD | -3.56% |
| 2004 Q3 | 1.2 Million CAD | 54.09% |
| 2003 Q4 | - CAD | 0.0% |
| 2003 FY | 566.41 Thousand CAD | -30.35% |
| 2003 Q1 | 813.17 Thousand CAD | 1526.36% |
| 2003 Q2 | - CAD | -100.0% |
| 2003 Q3 | - CAD | 0.0% |
| 2002 Q1 | 118.37 Thousand CAD | 0.0% |
| 2002 Q4 | 50 Thousand CAD | 0.0% |
| 2002 FY | 813.17 Thousand CAD | 586.97% |
| 2002 Q3 | 50 Thousand CAD | 0.0% |
| 2002 Q2 | - CAD | -100.0% |
| 2001 Q2 | - CAD | 0.0% |
| 2001 Q3 | - CAD | 0.0% |
| 2001 FY | 118.37 Thousand CAD | 0.0% |
| 2001 Q1 | - CAD | 0.0% |
| 2000 Q1 | - CAD | 0.0% |
| 2000 FY | - CAD | 0.0% |
| 1999 FY | - CAD | 0.0% |
| 1999 Q1 | - CAD | 0.0% |
| 1998 Q3 | - CAD | 0.0% |
| 1998 Q2 | - CAD | 0.0% |
| 1998 FY | - CAD | 0.0% |
| 1998 Q4 | - CAD | 0.0% |
| 1997 FY | - CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 87.826% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -21.694% |
| SQZ Biotechnologies Company | 27.47 Million USD | 81.74% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 88.435% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 83.149% |
| Mesoblast Limited | 118.7 Million USD | 95.774% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -428.983% |
| Genus plc | 233.1 Million USD | 97.848% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -71.178% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -273.344% |
| Marizyme, Inc. | 18.71 Million USD | 73.201% |
| ContraFect Corporation | 2.88 Million USD | -74.113% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -568.825% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -3602.339% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -246.824% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -115.661% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 11.349% |
| MultiCell Technologies, Inc. | 202.58 USD | -2476051.644% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 91.275% |
| EV Biologics, Inc. | 1.49 Million USD | -235.587% |
| Q BioMed Inc. | 4.1 Million USD | -22.049% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 84.846% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -696.123% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -308.364% |
| Biomind Labs Inc. | 735.54 Thousand USD | -581.972% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 97.076% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 61.405% |
| Skye Bioscience, Inc. | 4.61 Million USD | -8.687% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -464.845% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -3444.558% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 14.561% |
| IMV Inc. | 28.88 Million USD | 82.633% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -19403.822% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -122.114% |
| GB Sciences, Inc. | 1.75 Million USD | -185.123% |
| Alpha Cognition Inc. | 1.22 Million USD | -311.038% |
| HST Global, Inc. | 98.31 Thousand USD | -5001.952% |
| CSL Limited | 12.18 Billion USD | 99.959% |
| Halberd Corporation | 150 Thousand USD | -3244.125% |
| Enzolytics Inc. | 996.33 Thousand USD | -403.462% |
| Resverlogix Corp. | 6.49 Million USD | 22.721% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -950.511% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -1862.576% |
| argenx SE | 20 Million USD | 74.919% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 88.99% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -85.188% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -48958.073% |
| Genscript Biotech Corporation | 417.73 Million USD | 98.799% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -2400.393% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -109.206% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -2087.695% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 92.584% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -65.759% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1294.509% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 75.324% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -3274.405% |
| BioStem Technologies, Inc. | 4.71 Million USD | -6.469% |
| ONE Bio Corp. | 19.71 Million USD | 74.557% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -1905.016% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -1916.801% |
| Agentix Corp. | 50 Thousand USD | -9932.376% |
| LadRx Corporation | 33.6 Thousand USD | -14826.466% |
| Cell Source, Inc. | 9.25 Million USD | 45.795% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -563.338% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -563.338% |
| NovAccess Global Inc. | 2.19 Million USD | -128.021% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 29.078% |
| Itoco Inc. | 228.37 Thousand USD | -2096.451% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -2277.622% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -0.666% |
| Kadimastem Ltd | 891.22 Thousand USD | -462.841% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1148.277% |
| CytoDyn Inc. | 30.07 Million USD | 83.322% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -935.795% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -1325.673% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 35.854% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -3994.847% |
| Rebus Holdings, Inc. | 310 Thousand USD | -1518.125% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -5.932% |
| International Stem Cell Corporation | 4.17 Million USD | -20.062% |
| Bioxytran, Inc. | 1.92 Million USD | -160.581% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -7937.088% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -130.005% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 39.68% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 41.57% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -222.485% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -1771.712% |
| Neutra Corp. | 54.15 Thousand USD | -9162.479% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -174.109% |
| PureTech Health plc | 25.51 Million USD | 80.338% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -309.744% |
| IXICO plc | 472.02 Thousand USD | -962.7% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 67.64% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 91.944% |
| CSL Limited | 12.18 Billion USD | 99.959% |
| Cellectis S.A. | 92.77 Million USD | 94.593% |